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Summary The effects of dexamethasone, a synthetic glucocorticoid, and of N,N-dimethylformamide on in
vitro growth and differentiation and on proto-oncogene expression of human rhabdomyosarcoma cells were
studied. RD/18 clone cells (derived from the embryonal rhabdomyosarcoma cell line RD) treated with 100 nM
dexamethasone showed an almost complete block of differentiation: about 5% myosin-positive cells were
observed after 2 weeks of culture in dexamethasone-supplemented differentiation medium, compared to 20%
of untreated cultures. Dexamethasone also induced a 20-30% growth inhibition and a more flattened
morphology. The treatment with N,N-dimethylformamide induced a significantly increased proportion of
myosin-positive cells (reaching about 30%) and a 40% growth inhibition.
Induction of differentiation inversely correlated with the levels of c-myc proto-oncogene expression: after a 2
week culture dexamethasone-treated cells showed the highest c-myc expression and N,N-dimethylformamide-
treated cells the lowest. Culture conditions per se down-modulated c-erbBI and up-regulated c-jun expression,
with no relationship to the differentiation pattern. Other proto-oncogenes were not expressed (c-sis, N-myc,
c-mos, c-myb) or were not modulated (c-fos, c-raj).
Therefore dexamethasone and N,N-dimethylformamide, both causing a decreased growth rate, showed
opposing actions on myogenic differentiation and on c-myc proto-oncogene expression of human rhab-
domyosarcoma cells.
Rhabdomyosarcoma cell lines of human and animal origin
have proved to be interesting models for a dynamic study of
differentiation of solid tumours in vitro (Dickman et al.,
1991). Myogenic differentiation can be monitored by mor-
phological criteria (formation of multinuclear myotube-like
structures) as well as biochemical markers (such as myosin
expression and creatine phosphokinase activity).
Different substances have been found able to induce rhab-
domyosarcoma cells to differentiate along the myogenic path-
way: polar compounds, such as N,N-dimethylformamide
(Dexter, 1977; Nicoletti et al., 1992) and N-methylformamide
(Gerharz et al., 1989b); retinoic acid (Garvin et al., 1986;
Gabbert et al., 1988); some antineoplastic agents (Lollini et
al., 1989); 12-O-tetradecanoylphorbol-13-acetate (Aguanno et
al., 1990). The search for differentiation inducers could have
therapeutic implications (Waxman et al., 1988).
Glucocorticoids can interact in vitro with normal myogenic
differentiation and proliferation (Guerriero & Florini, 1980;
Florini, 1987; Sklar & Brown, 1991) and increase the expres-
sion of acetylcholine receptors on normal myoblasts (Kaplan
et al., 1990); however, their effects on the malignant myo-
genic counterpart remain to be determined.
In this paper, we tested the activity of a synthetic glucocor-
ticoid (dexamethasone) on proliferation and differentiation of
human embryonal rhabdomyosarcoma clone cells, in com-
parison to that of a known inducer of myogenic differentia-
tion, N,N-dimethylformamide (Dexter, 1977).
Materials and methods
Cells
RD/18 clone was obtained in our laboratory (Lollini et al.,
1991) from the human embryonal rhabdomyosarcoma RD
cell line (purchased from Flow Laboratories, Va., USA) and
was used between the 10th and the 20th in vitro passages
after cloning. Cells were routinely maintained in Dulbecco's
modified Eagle medium supplemented with 100 U ml-' peni-
cillin, 100jigml-I streptomycin (hereafter referred to as
DMEM) and with 10% foetal calf serum (FCS). All media
constituents were purchased from GIBCO, Paisley, Scotland.
Cell cultures were incubated at 37TC in a humidified 7% CO2
atmosphere. Cells were monitored for mycoplasma contamin-
ation by fluorescent staining with Hoechst 33258 (Chen,
1977) and found to be mycoplasma-free.
Cell treatment
Cells were seeded in T25 flasks (Falcon Plastics, Oxnard,
USA) or in 24 well plates (Costar, Cambridge, MA, USA) at
10,000 cells cm-2 in DMEM + 10% FCS to favour cell
attachment. Since it has been reported that media with a low
serum content can promote myogenic differentiation (Dym &
Yaffe, 1979; Blau & Webster, 1981; Davis et al., 1987; Ger-
harz et al., 1989a; Nicoletti et al., 1992), all cultures (controls
included) were switched to DMEM + 1% FCS 24 h after
seeding (day 1). Dexamethasone (Sigma, St Louis, MO,
USA), dissolved as 20 mM stock solution in ethanol and
diluted in DMEM + 1% FCS, was added to some cultures at
day I (immediately after medium replacement) at final con-
centrations ranging 10-1,000 nM. Controls with ethanol-
containing medium were run in parallel.
N,N-dimethylformamide (Fluka Chemie AG, Buchs, Swit-
zerland) was added to cultures at day 4 at a final concentra-
tion of0.5% (Nicoletti et al., 1992). This schedule of treatment
with N,N-dimethylformamide was chosen, after preliminary
experiments, as that capable of giving an increased myogenic
differentiation concomitantly to an inhibition of proliferation
comparable to that observed with dexamethasone. Addition
of N,N-dimethylformamide before day 4 reduced substan-
tially cell growth without a net effect on cell differentiation.
Treatments lasted till the end of the experiment, with
medium renewal every other day.
Evaluation ofdifferentiation
Cells were harvested at different times, counted and centri-
fuged at 400 g for 10min onto glass slides. Cytocentrifuge
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slides were immediately fixed with methanol:acetone (3:7) at
-20C and stained as described (Nanni et al., 1986) in an
indirect immunofluorescence assay with BF-G6 monoclonal
antibody recognising embryonic myosin (Schiaffino et al.,
1986). After washing off the unbound fluorescein-conjugated
second antibody (Technogenetics, Milano, Italy), cell nuclei
were stained with ethidium bromide (1OOLgml-1 in phos-
phate-buffered saline) for 5min. After extensive washings
and mounting, slides were examined under a Reichert Biovar
microscope equipped for phase contrast and green-red
fluorescence. At least 300 cell elements (either mono- or
multinuclear) in random fields were scored at 312.5 x for
determining the percentage of myosin-positive cells. At least
200 nuclei in random fields were scored at 1,250 x for the
simultaneous determination of the number of nuclei per cell
and of myosin positivity. Statistical evaluation was per-
formed by Student's t test.
Proto-oncogene expression
Total RNA was isolated using the guanidine chloride method
(Cox, 1968). RNA samples (20fg) were electrophoresed in
1% agarose gels containing 2.2 M formaldehyde, transferred
to Gene Screen Plus membrane (New England Nuclear) by
electroblotting and baked for 2 h at 80°C in vacuo. Hybri-
disation and washing conditions were as previously described
(Dolcetti et al., 1988). Levels of gene expression were deter-
mined by densitometric scanning (ISCO Inc., Neb., USA).
Molecularly cloned DNA fragments used as hybridisation
probes were:
- the 1.6 kb ClaI-EcoRI fragment of pHSR-1 (human c-
myc) (Alitalo et al., 1983);
- the 1.0kb EcoRI-BamHI fragment of pNB-1 (human
N-myc) (Schwab et al., 1983);
- the 3.0 kb BglII fragment of pHM2A (human c-mos)
(Watson et al., 1982);
- the 1.2 kb PstI fragment of human c-myb cDNA
(Franchini et al., 1983);
- the 2.9 kb EcoRI fragment of p627 (human c-raf-1)
(Bonner et al., 1986);
- the 1.2 kb PstI fragment of Assv-11 clone 1 (v-sis) (Rob-
bins et al., 1981);
- the 1.8 kb EcoRI fragment of pHER-A64-1 (human
EGFr) (Ullrich et al., 1984);
- the 1.0 kb PstI fragment of v-fos (Curran et al., 1982);
- the 2.6 kb EcoRI fragment of JAC-1 (murine c-jun)
(Ryder & Nathans, 1989);
- the 0.70 kb EcoRI-BamHI fragment of pHFJ3A-3'UT
(human P-actin) (Ponte et al., 1983).
Results
In vitro growth anddifferentiation
RD/18 clone cells were cultured for 14 days in differentiation
medium supplemented with 10-1,000 nM dexamethasone
(from day 1) or with 0.5% N,N-dimethylformamide (from
day 4) (Figure 1). Myosin expression, observed in about 20%
untreated cells, was strongly inhibited by 100-1,000 nM dex-
amethasone, whereas the 10 nM dose was close to control. On
the contrary, N,N-dimethylformamide caused a significant
increase in the percentage of myosin-positive cells, reaching
about 30%. Even though dexamethasone and N,N-dimethyl-
formamide affect rhabdomyosarcoma differentiation differ-
ently, they share an inhibitory activity on cell growth (Figure
2): in particular dexamethasone caused a growth inhibition
that approached 35% at the highest dosage tested.
Figure 3 shows the kinetics of the induction of myogenic
differentiation by N,N-dimethylformamide and the inhibition
by dexamethasone. It should be noted that myosin expression
in RD/18 rhabdomyosarcoma cells rises throughout 2 weeks,
starting from negligible levels. Dexamethasone affected the
rise in the percentage ofmyosin-positive cells: such effect was
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Figure 1 Effect of dexamethasone and N,N-dimethylformamide
on the percentage ofmyosin-positive cells of RD/18 cells cultured
for 14 days in DMEM+1% FCS. Mean and standard error from
3-5 experiments is shown. Significance of difference vs untreated
cells: *, P<0.05; **, P<0.01, Student's t test.
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Figure 2 Effect of dexamethasone and N,N-dimethylformamide
on cell yield and myosin-positivity of RD/18 cells cultured for 14
days in DMEM+1% FCS. Data are expressed as % variation
over untreated cells. Mean and standard error from 3-5
experiments is shown.
already detectable in 7-day cultures. A more flattened morpho-
logy was observed in dexamethasone-treated cells (Figure 4).
The effect of dexamethasone seemed to be specifically
mediated by the glucocorticoid receptor, since the hormone
effect was almost completely neutralised by a 100-fold molar
excess of the inactive glucocorticoid cortexolone (data not
shown).
The myogenic differentiation process involves somatic cell
fusion with formation of multinuclear elements: therefore the
possibility that the observed effects (and in particular the
dexamethasone-induced inhibition of myogenic differentia-
tion) could be due to a modulation of multinucleation has
been investigated. The percentage of nuclei in myosin-posi-
tive cells paralleled that of myosine-positive cells in whatever
treated culture (Table I). No variation in the proportion of
multinuclear cells was observed. Therefore dexamethasone-
induced inhibition of the percentage of myosin-positive cells
was not attributable to an increase in cell fusion.
Proto-oncogene expression
Proto-oncogene expression was evaluated on 2-week cultures
in which myogenic differentiation had been up- or down-
modulated by N,N-dimethylformamide and by dexametha-
sone, respectively. In order to better evaluate the relationship
between proliferation and differentiation, two controls were
performed: untreated cells from 14-day cultures (in a plateau
growth phase, about 20% myosin-positive cells) and un-676 C. DE GIOVANNI et al.
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Figure 3 Kinetics of growth a, and of myosin expression b, in
RD/18 cells treated with dexamethasone (DX) (from day 1) and
N,N-dimethylformamide (DMF) (from day 4). A representative
experiment is reported; mean and standard error from three
replicates is shown. Untreated cells significantly different
(P<0.05 at least) from DX-treated cells from day 7 and from
DMF-treated cells from day 11.
treated cells from a 4-day culture (in logarithmic growth
phase, undifferentiated) (see Figure 3). Quantification of
proto-oncogene expression was performed by hybridising
RNAs with a probe for P-actin as an internal standard. In
each case, the intensity of P-actin signal was proportional to
the respective amount of RNA loaded in the gel as deter-
mined by ethydium bromide staining.
The level ofc-myc proto-oncogene expression was inversely
correlated to the induction of myogenic differentiation
(Figure 5, top). A decreased c-myc expression was observed
with increasing time in culture; the least differentiated dexa-
methasone-treated cultures retained the highest level of ex-
pression after a 14-day culture in differentiation medium,
whereas N,N-dimethylformamide-treated cultures showed the
lowest expression.
The achievement of a high cell density, observed in all
treated 2-week cultures (see Figure 3), was found to down-
Table I Myosin-positivity and cell fusion parameters in RD/18
cultures treated with 100 nM dexamethasone (DX) or with 0.5%
N,N-dimethyformamide (DMF)
Treatment ofcells
None DX DMF
Myosin-positive cells (%) 18.2±0.8 6.8± 1.2 26.4± 3.9
Nuclei in myosin-positive
cells/total nuclei (%) 18.0±0.8 7.4± 1.6 26.8±4.5
Multinuclear cells (%) 4.8±0.6 3.5±0.3 3.8±0.6
Nuclei in multinuclear
cells/total nuclei (%) 9.8±1.2 7.0±0.8 9.3±2.4
Data from 14-day cultures. Mean and standard error of three
replicates of a single, representative experiment is shown.
Figure 4 RD/18 cell morphology in untreated a, 100 nM dexa-
methasone-treated b, and 0.5% N,N-dimethylformamide-treated
c, cultures 7 days after cell seeding. Phase contrast, x 100.
modulate c-erbB expression and to up-modulate c-jun ex-
pression (Figure 5, centre and bottom, respectively).
Other proto-oncogenes were not expressed (c-sis, N-myc,
c-mos, c-myb) or were not modulated (c-fos, c-raj) (data not
shown).
Discussion
In this paper we have described the opposing actions on
myogenic differentiation of human rhabdomyosarcoma cells
played by a potent synthetic glucocorticoid (dexamethasone)
and by a known differentiation inducer (N,N-dimethylform-
amide). Both substances decreased cell proliferation, but
affected myogenic differentiation differently: in particular
dexamethasone was able to inhibit almost completely mor-
phological and biochemical myogenic differentiation of
human rhabdomyosarcoma cells, even if it decreased growth
rate. Opposing actions have been found also on c-myc ex-
pression: N,N-dimethylformamide-treated cells showed a
reduced expression of c-myc, in agreement with the reduction
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Figure 5 c-myc (top), c-erbBl (centre) and c-jun (bottom) expres-
sion levels in 14-day RD/18 N,N-dimethylformamide-treated
(lane 1), dexamethasone-treated (lane 2), untreated (lane 3) cul-
tures and in 4-day untreated cultures (lane 4). Proto-oncogene/p-
actin ratio, based on densitometric analysis, is also reported.
n.d. = not detectable.
in growth rate, on the contrary a sustained expression was
found in dexamethasone-treated cultures, despite their slower
growth rate.
Since data on the effects of dexamethasone on rhabdomyo-
sarcoma cells are not reported in the literature, the results
presented here will be discussed in comparison with those
reported for normal myogenic models.
The relationships between proliferation and differentiation
of human solid tumours have not yet been clarified. In
particular, differentiation inducers active on rhabdomyosar-
coma consist of a heterogeneous group of compounds (see
Introduction), with the common ability to affect growth rate.
Decreased proliferation could be a condition allowing rhab-
domyosarcoma cell differentiation to occur, as also suggested
by the inducing effect of nutrient-deprived differentiation
media (Nanni et al., 1986; Gerharz et-al., 1989a).
N,N-dimethylformamide inhibited cell proliferation and
increased myogenic differentiation of rhabdomyosarcoma
cells, as shown by data presented here and in agreement with
the results obtained with other cell lines of human and rat
origin (Dexter, 1977; Nicoletti et al., 1992).
Some agents with inhibitory effect on normal myogenic
differentiation have been reported: tumour necrosis factor
(TNF) (Miller et al., 1988), TGFPI (Florini et al., 1986) and
FGF (Florini & Magri, 1989). Only FGF has mitogenic
activity, whereas TNF and TGFP barely affected cell pro-
liferation.
Dexamethasone in our model shows a peculiar behaviour,
since it decreases growth rate, without affecting cell viability,
and strongly inhibits rhabdomyosarcoma differentiation. Two
different hypotheses could be suggested: either decreasing
proliferation is not per se a means to induce myogenic
differentiation, or dexamethasone plays two opposing
actions: a inhibitory role that turns off the stimulatory one.
Possible mechanisms for dexamethasone action can be sug-
gested on the basis of the activities found in normal myo-
genic models. Dexamethasone induces glutamine synthetase
in L6 myoblasts, with a significant decrease of total protein
synthesis (Max et al., 1987). Moreover, its interference with
growth factor circuits has been documented in different nor-
mal myogenic models (Whitson et al., 1989; Southorn &
Palmer, 1990; Poon et al., 1991).
It should be underlined, however, that the effects of gluco-
corticoids on normal myogenic differentiation in vitro are
controversial: myotube formation and myosin expression in
human myoblasts may be either stimulated by glucocorti-
coids (Sklar & Brown, 1991) or unaffected (Kaplan et al.,
1990).
The possibility that rhabdomyosarcoma responsiveness to
dexamethasone might be altered should also be taken into
account.
It has been reported that expression of different oncogenes
can alter glucocorticoid effects (Hamilton & DeFranco, 1989;
Matin et al., 1990; Basu & Lazo, 1991). Different oncogenes
can be involved in myogenic differentiation (see for example
Alema & Tato, 1987; Claycomb & Lanson, 1987; Leibovitch
et al., 1987; Florini & Magri, 1989; Dickman et al., 1991).
The relationship between proliferation, differentiation and
c-myc expression level has been widely studied in myogenic
models but, nevertheless, not yet fully clarified (Olson et al.,
1991). A transfected c-myc expression system could suppress
myogenesis, independently of other known positive (MyoDI,
myogenin) or negative (Id) regulators of myogenic differen-
tiation (Miner & Wold, 1991).
Our data on a rhabdomyosarcoma model show an inverse
correlation between c-myc expression levels and induction of
differentiation: therefore this proto-oncogene can be modu-
lated and play a role also in the differentiation programme of
malignant myogenic cells.
In RD/18 cultures c-fos and c-raf proto-oncogenes were
expressed, but were not modulated either by culture or by
differentiation. In a well-studied rat rhabdomyosarcoma
model, expression of these two proto-oncogenes was cor-
related to induction of differentiation (Gabbert et al., 1990).
Different origins of rhabdomyosarcomas (human vs rat, spon-
taneous vs dimethylbenzathracene-induced) could account for
the different role played by these proto-oncogenes.
Among the other proto-oncogenes studied here, interesting
behaviors were observed for c-jun and c-erbBl (human EGF
receptor), that were up-modulated or down-modulated by
increasing time in culture, with no relation to the differ-
entiation level reached by the culture. They actually seem to
be related to the achievement of a high cell density.
In a normal myogenic model of murine origin, EGF bind-
ing was found to decrease rapidly when cells differentiated
(Lim & Hauschka, 1984). RD/18 rhabdomyosarcoma cells
retain the down-modulation of EGF receptor even in the
absence of a complete differentiation as can be achieved with
normal cells: therefore, we can hypothesise that EGF recep-
tor down-modulation could be associated to proliferative
ability of rhabdomyosarcoma cell culture rather than to a
terminally differentiated status.
In conclusion, the in vitro human rhabdomyosarcoma
model presented here seemed to be suitable to distinguish
between effects on proliferation and differentiation, as shown
by the uncoupling between growth inhibition and differen-
tiation observed in dexamethasone-treated cultures and by
the modulation of c-jun and c-erbBl proto-oncogene expres-
sion.
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